nobiletin has been researched along with Liver Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, W; Ho, CT; Li, M; Li, S; Liu, J; Liu, S; Lv, K; Wang, J; Wang, L; Wang, M; Wu, J; Zhao, H | 1 |
| Dusabimana, T; Kim, H; Kim, HJ; Kim, SR; Park, SW | 1 |
2 other study(ies) available for nobiletin and Liver Diseases
| Article | Year |
|---|---|
Nobiletin Protects against Acute Liver Injury via Targeting c-Jun N-Terminal Kinase (JNK)-Induced Apoptosis of Hepatocytes.
Topics: Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Flavones; Hepatocytes; Humans; Interferon-gamma; JNK Mitogen-Activated Protein Kinases; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Protective Agents; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2020 |
Nobiletin ameliorates hepatic ischemia and reperfusion injury through the activation of SIRT-1/FOXO3a-mediated autophagy and mitochondrial biogenesis.
Topics: Animals; Autophagy; Flavones; Forkhead Box Protein O3; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Organelle Biogenesis; Reperfusion Injury; Signal Transduction; Sirtuin 1 | 2019 |